Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
University of Florida
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05000294CT.gov Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gallbladder Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tivozanib (this asset) | University of Florida | P1/2 | CC · 47 |
| Fluorouracilum | Lisata Therapeutics, Inc. | P2 | BBB |
| Capecitabine | Merck Sharp & Dohme LLC | P3 | BB |
| Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2 | BB |
| Desflurane | Tokyo Medical and Dental University | P4 | BB |
| Sevoflurane | Tokyo Medical and Dental University | P4 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Epirubicin | Merck Sharp & Dohme LLC | P2 | BB |
+42 more in the Gallbladder Cancer cohort
Other indications for Tivozanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | B · 62 |
| Hepatocellular Carcinoma | — | P2 | B · 58 |
| Nonpapillary Renal Cell Carcinoma | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tivozanib in Gallbladder Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tivozanib-gallbladder-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →